Chronic insomnia is persistent difficulty initiating or maintaining sleep with daytime impairment. It commonly arises from interacting factors: acute stress or life events, untreated mood or anxiety disorders, chronic pain or medical conditions, circadian rhythm misalignment from shift work, and environmental or social factors such as noisy urban housing. Left untreated, chronic insomnia increases risk of daytime cognitive decline, mood disorders, workplace accidents, and reduced quality of life; public health authorities highlight its broad societal impact.
Evidence-based psychological therapies
The strongest evidence supports Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment. Charles M. Morin Université Laval and Colleen E. Carney Ryerson University are among clinicians and researchers who have described CBT-I’s core components and tested its efficacy in randomized trials. CBT-I targets maladaptive behaviors and unhelpful beliefs about sleep through techniques such as stimulus control and sleep restriction, alongside cognitive restructuring and relaxation training. Clinical practice guidance from Qaseem A American College of Physicians recommends CBT-I as the preferred initial approach for adults with chronic insomnia because it produces durable improvements in sleep without the adverse effects associated with long-term medications. CBT-I is effective across ages and can be adapted to comorbid psychiatric or medical conditions, though tailoring and clinician training improve outcomes.
Pharmacological and chronotherapeutic options
When immediate symptom relief is necessary or CBT-I is inaccessible, short-term pharmacotherapy can be effective for sleep initiation or maintenance. Hypnotic medications such as benzodiazepine receptor agonists reduce sleep latency and increase total sleep time in the short term, but they carry risks of tolerance, dependence, daytime sedation, and increased fall risk in older adults. Clinical guidance stresses limiting duration and regularly reviewing the need for continued medication. Melatonin and melatonin receptor agonists are useful primarily for circadian-related insomnia and in older adults, with a different side-effect profile. Bright light therapy and timed melatonin can re-align circadian rhythms in shift work or delayed sleep-wake phase disorder. Pharmacological choices should be individualized, balancing efficacy against side effects and the patient’s medical and social context.
Access, cultural and environmental considerations
Access to trained CBT-I practitioners varies by region and health system; many areas lack sufficient providers, which leads to greater reliance on medication. Digital CBT-I programs and stepped-care models have evidence of benefit and can expand access, though they may be less effective for people with complex psychiatric or medical comorbidity. Cultural beliefs about sleep, work schedules, caregiving responsibilities, and housing conditions can influence both causes and feasible treatments—interventions that ignore these realities often fail. Environmental measures such as improving bedroom quietness, light exposure, and work-time policies can be important adjuncts to individual therapy. Effective management combines evidence-based therapies with attention to the person’s life context and priorities.